Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Treatment Trial Using AbGn-168H to Treat Steroid Refractory Acute Graft-vs.-Host Disease (aGVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

NCT02436460 is registered in ClinicalTrials.gov with AbGenomics B.V Taiwan Branch as lead sponsor.

NCT NCT02436460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02436460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Treatment Trial Using AbGn-168H to Treat Steroid Refractory Acute Graft-vs.-Host Disease (aGVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Lead sponsor
AbGenomics B.V Taiwan Branch
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2015
Completion date
March 31, 2016
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute graft versus host disease